CHS-114 (Tagmokitug) in Combination With Toripalimab

October 14, 2026: Coherus Oncology, Inc. (NASDAQ: CHRS) announced it will release interim clinical data from its tagmokitug program on October 28, 2026, with a management webcast scheduled from 4:30 p.m. to 6:00 p.m. EDT. The update will cover tagmokitug, a cytolytic anti-CCR8 antibody, in combination with toripalimab across multiple solid tumors.

The company states tagmokitug is in Phase 1b/2a studies in patients with advanced solid tumors, including head and neck squamous cell carcinoma, colorectal cancer, gastric cancer, gastro-esophageal junction cancer, esophageal adenocarcinoma, and esophageal squamous cell carcinoma. The October 28 webcast is the upcoming catalyst mentioned.

The release also notes Coherus markets LOQTORZI (toripalimab-tpzi), a PD-1 inhibitor approved for relapsed/metastatic nasopharyngeal carcinoma, and is developing casdozokitug, an IL-27 antagonistic antibody in a Phase 2 study for first-line hepatocellular carcinoma. No efficacy or safety results were disclosed in this announcement.